In addition, losses to follow-up were reported as 501 patients in the
chlorthalidone group and 338 patients in the doxazosin group. This has been
changed to losses of 545 patients and 361 patients, respectively, because
the authors modified the definition of loss to follow-up. Originally, the
definition was based on declaration of loss by a clinic site. The new definition
includes this plus vital status unknown at trial closeout, the period of October
15, 1999, through February 15, 2000.